Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrodotoxin TQT Study in Healthy Adults
NCT04083833Phase 1Completed
- Sponsor
- Dogwood Therapeutics, Inc.
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tetrodotoxin in chemotherapy-induced peripheral neuropathy (CIPN) and cancer pain (2 arms), sponsored by Dogwood Therapeutics, Inc. Primary endpoint: Cardiodynamic Effect (QT/QTc Intervals) at 24 hours. Started Feb 2018; status: completed.
02
Drugs
tetrodotoxin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)cancer pain
Beyond the preview
Go deeper on NCT04083833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083833.